Pyxis Oncology, Inc.
Pyxis Oncology, Inc. (PYXS) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · PYXS · as of Jun 8, 2026
Activity summary
Buy transactions
2
P-Purchase only
Sell transactions
3
12 Months
Buy/Sell ratio
0.67
Buy/Sell (by trades)
Overall sentiment
Pyxis Oncology, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
PYXS insider buying and selling by quarter
PYXS insider selling · PYXS insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · PYXS ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
PYXS executive sell shares · PYXS board member insider trading · PYXS insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Mar 24, 2026 | Wadhane Jitendra Prin Fin & Acct Officer | Award | 109,461 | — | Form 4 |
| Apr 14, 2025 | HUMPHREY RACHEL Director | Sale | 1,400 | $1K | Form 4 |
| Apr 17, 2025 | HUMPHREY RACHEL Director | Sale | 200 | $194 | Form 4 |
| Apr 21, 2025 | HUMPHREY RACHEL Director | Sale | 13,896 | $14K | Form 4 |
| Nov 26, 2024 | Connealy Pamela Ann CFO & COO | Purchase | 83,400 | $163K | Form 4 |
| Nov 26, 2024 | Connealy Pamela Ann CFO & COO | Purchase | 5,450 | $11K | Form 4 |
| Jun 7, 2024 | Palani Santhosh Director | Award | 6,000 | — | Form 4 |
| Mar 26, 2024 | Connealy Pamela Ann CFO & COO | Award | 328,710 | — | Form 4 |
| Mar 26, 2024 | FLAVIN JOHN L Director | Award | 35,219 | — | Form 4 |
| Mar 26, 2024 | Cline Darren S Director | Award | 35,219 | — | Form 4 |
| Mar 26, 2024 | Lewis-Hall Freda C Director | Award | 35,219 | — | Form 4 |
| Mar 26, 2024 | Dupont Jakob Director | Award | 38,741 | — | Form 4 |
| Mar 26, 2024 | HUMPHREY RACHEL Director | Award | 38,741 | — | Form 4 |
| Mar 26, 2024 | Wadhane Jitendra SVP, Chief Accounting Officer | Award | 131,484 | — | Form 4 |
| Nov 29, 2023 | Connealy Pamela Ann CFO and COO | Other | 36,949 | $52K | Form 4 |
| Nov 15, 2023 | Wadhane Jitendra CAO | Award | 40,000 | — | Form 4 |
| Sep 28, 2023 | Connealy Pamela Ann CFO and COO | Purchase | 8,000 | $15K | Form 4 |
| Sep 27, 2023 | Wadhane Jitendra CAO | Purchase | 2,500 | $5K | Form 4 |
| Sep 27, 2023 | Connealy Pamela Ann CFO and COO | Purchase | 6,426 | $12K | Form 4 |
| Sep 25, 2023 | Wadhane Jitendra CAO | Purchase | 5,000 | $9K | Form 4 |
| Sep 25, 2023 | Connealy Pamela Ann CFO and COO | Purchase | 12,000 | $20K | Form 4 |
| Sep 22, 2023 | Wadhane Jitendra CAO | Purchase | 2,500 | $4K | Form 4 |
| Sep 22, 2023 | Connealy Pamela Ann CFO and COO | Purchase | 5,000 | $9K | Form 4 |
| Sep 14, 2023 | Sullivan Lara President and CEO · Director | Sale | 100 | $225 | Form 4 |
| Sep 18, 2023 | Sullivan Lara President and CEO · Director | Sale | 8,541 | $18K | Form 4 |
Wadhane Jitendra
Prin Fin & Acct Officer
Date
Mar 24
Shares
109,461
Price
—
Value
—
Connealy Pamela Ann
CFO & COO
Date
Nov 26
Shares
83,400
Price
$1.96
Value
$163K
Wadhane Jitendra
SVP, Chief Accounting Officer
Date
Mar 26
Shares
131,484
Price
—
Value
—
Connealy Pamela Ann
CFO and COO
Date
Sep 28
Shares
8,000
Price
$1.87
Value
$15K
Connealy Pamela Ann
CFO and COO
Date
Sep 27
Shares
6,426
Price
$1.85
Value
$12K
Connealy Pamela Ann
CFO and COO
Date
Sep 25
Shares
12,000
Price
$1.67
Value
$20K
Sullivan Lara
President and CEO · Director
Date
Sep 14
Shares
100
Price
$2.25
Value
$225
Sullivan Lara
President and CEO · Director
Date
Sep 18
Shares
8,541
Price
$2.10
Value
$18K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About PYXS insider trading
PYXS insider trades
Pyxis Oncology, Inc. (PYXS) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Wadhane Jitendra (Prin Fin & Acct Officer). Over the past 12 months, 1 insiders have filed transactions with the SEC. PYXS insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Pyxis Oncology, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
PYXS insider trading · 5 questionsThe insiders of Pyxis Oncology, Inc. (PYXS) include executives and directors such as Wadhane Jitendra (Prin Fin & Acct Officer), among others. Over the past 12 months, 1 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026